PhoreMost Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $58.8M

  • Investors
  • 17

PhoreMost General Information

Description

Operator of a drug target identification and drug discovery company intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context and then uses these functionally validated protein fragments to inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 7, The Works
  • Unity Campus
  • Pampisford CB22 3FT
  • England, United Kingdom
+44 01223
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Vertical(s)
Corporate Office
  • Unit 7, The Works
  • Unity Campus
  • Pampisford CB22 3FT
  • England, United Kingdom
+44 01223

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PhoreMost Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 10-Sep-2024 $58.8M Completed Pre-Clinical Trials
6. Early Stage VC (Series A) 30-Apr-2018 Completed Pre-Clinical Trials
5. Grant 27-Apr-2018 Completed Pre-Clinical Trials
4. Early Stage VC 03-Mar-2017 Completed Pre-Clinical Trials
3. Grant 13-May-2015 Completed Pre-Clinical Trials
2. Seed Round 11-Mar-2015 $6.12M $6.12M Completed Pre-Clinical Trials
1. University Spin-Out 01-Apr-2014 Completed Startup
To view PhoreMost’s complete valuation and funding history, request access »

PhoreMost Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A1 Ordinary
A Ordinary
A Ordinary
A Ordinary 46,700 $0.001307 $55.95 $55.95 1x $55.95 7.83%
A Ordinary 65,311 $0.001307 $50.81 $50.81 1x $50.81 10.96%
To view PhoreMost’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

PhoreMost Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug target identification and drug discovery company intended to identify new targets or drugs for future
Biotechnology
Pampisford, United Kingdom
50 As of 2023

Leiden, Netherlands
 

Montreal, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PhoreMost Competitors (68)

One of PhoreMost’s 68 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ncardia Venture Capital-Backed Leiden, Netherlands
Cyclenium Pharma Corporate Backed or Acquired Montreal, Canada
Integral Molecular Private Debt Financed Philadelphia, PA
Compass Therapeutics Formerly VC-backed Boston, MA
Circle Pharma Venture Capital-Backed South San Francisco, CA
You’re viewing 5 of 68 competitors. Get the full list »

PhoreMost Patents

PhoreMost Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202407128-D0 Methods of protein engineering and functional screening Inactive 20-May-2024
GB-202319002-D0 Methods of protein engineering and functional screening Inactive 13-Dec-2023
GB-202314894-D0 Methods of protein engineering and functional screening Inactive 28-Sep-2023
GB-202111193-D0 Pharmaceutical compounds Inactive 03-Aug-2021
GB-202110820-D0 Targeted protein degradation Inactive 28-Jul-2021
To view PhoreMost’s complete patent history, request access »

PhoreMost Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhoreMost Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Astellas Venture Management Corporate Venture Capital Minority
BGF (Financial Services) Growth/Expansion Minority
Meltwind Advisory Venture Capital Minority
Trend Investment Group Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

PhoreMost FAQs

  • When was PhoreMost founded?

    PhoreMost was founded in 2014.

  • Where is PhoreMost headquartered?

    PhoreMost is headquartered in Pampisford, United Kingdom.

  • What is the size of PhoreMost?

    PhoreMost has 50 total employees.

  • What industry is PhoreMost in?

    PhoreMost’s primary industry is Biotechnology.

  • Is PhoreMost a private or public company?

    PhoreMost is a Private company.

  • What is PhoreMost’s current revenue?

    The current revenue for PhoreMost is .

  • How much funding has PhoreMost raised over time?

    PhoreMost has raised $83M.

  • Who are PhoreMost’s investors?

    5Y Capital, Astellas Venture Management, BGF (Financial Services), Meltwind Advisory, and Trend Investment Group are 5 of 17 investors who have invested in PhoreMost.

  • Who are PhoreMost’s competitors?

    Ncardia, Cyclenium Pharma, Integral Molecular, Compass Therapeutics, and Circle Pharma are some of the 68 competitors of PhoreMost.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »